CN118580183A - A method for preparing an edoxaban intermediate - Google Patents
A method for preparing an edoxaban intermediate Download PDFInfo
- Publication number
- CN118580183A CN118580183A CN202310192696.1A CN202310192696A CN118580183A CN 118580183 A CN118580183 A CN 118580183A CN 202310192696 A CN202310192696 A CN 202310192696A CN 118580183 A CN118580183 A CN 118580183A
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- added
- preparation
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 15
- HGVDHZBSSITLCT-JLJPHGGASA-N Edoxaban Chemical compound N([C@H]1CC[C@@H](C[C@H]1NC(=O)C=1SC=2CN(C)CCC=2N=1)C(=O)N(C)C)C(=O)C(=O)NC1=CC=C(Cl)C=N1 HGVDHZBSSITLCT-JLJPHGGASA-N 0.000 title description 4
- 229960000622 edoxaban Drugs 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 60
- 238000006243 chemical reaction Methods 0.000 claims abstract description 36
- 238000002360 preparation method Methods 0.000 claims abstract description 26
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 60
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 238000003756 stirring Methods 0.000 claims description 20
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 11
- 239000003960 organic solvent Substances 0.000 claims description 11
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 2
- 239000012535 impurity Substances 0.000 abstract description 5
- 230000035484 reaction time Effects 0.000 abstract description 5
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 3
- 238000007711 solidification Methods 0.000 abstract description 3
- 230000008023 solidification Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 238000011031 large-scale manufacturing process Methods 0.000 abstract 1
- 239000008213 purified water Substances 0.000 description 19
- 239000002585 base Substances 0.000 description 15
- WJRKNLONLOMALV-UHFFFAOYSA-N 5-chloropyridine Chemical compound ClC1=C=NC=C[CH]1 WJRKNLONLOMALV-UHFFFAOYSA-N 0.000 description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 11
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- 239000012065 filter cake Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 206010051055 Deep vein thrombosis Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000010378 Pulmonary Embolism Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 206010047249 Venous thrombosis Diseases 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000009776 industrial production Methods 0.000 description 3
- 238000013341 scale-up Methods 0.000 description 3
- 206010003658 Atrial Fibrillation Diseases 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 206010014522 Embolism venous Diseases 0.000 description 2
- 208000032109 Transient ischaemic attack Diseases 0.000 description 2
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000012805 post-processing Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 201000010875 transient cerebral ischemia Diseases 0.000 description 2
- 208000004043 venous thromboembolism Diseases 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229960005378 edoxaban tosylate Drugs 0.000 description 1
- ZLFZITWZOYXXAW-QXXZOGQOSA-N edoxaban tosylate Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.N([C@H]1CC[C@@H](C[C@H]1NC(=O)C=1SC=2CN(C)CCC=2N=1)C(=O)N(C)C)C(=O)C(=O)NC1=CC=C(Cl)C=N1 ZLFZITWZOYXXAW-QXXZOGQOSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000009875 water degumming Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pyridine Compounds (AREA)
Abstract
Description
技术领域Technical Field
本发明涉及药物化学领域,具体涉及一种艾多沙班中间体的制备方法。The present invention relates to the field of pharmaceutical chemistry, and in particular to a method for preparing an edoxaban intermediate.
背景技术Background Art
甲苯磺酸艾多沙班片由日本第一三共开发,为选择性Xa因子抑制剂,2011年4月于日本上市,用于静脉血栓栓塞症(VTE);2015年1月美国获批,用于降低非心脏瓣膜病引起的房颤患者卒中和危险血栓(系统性栓塞)风险;2018年12月进入中国,用于伴有一个或多个风险因素(如充血性心力衰竭、高血压、年龄≥75岁、糖尿病、既往卒中或短暂性脑缺血发作(TIA)病史)的非瓣膜性房颤(NVAF)成人患者,预防卒中和体循环栓塞;用于治疗成人深静脉血栓(DVT)和肺栓塞(PE),以及预防成人深静脉血栓和肺栓塞复发。其结构如下:Edoxaban tosylate tablets were developed by Daiichi Sankyo of Japan. They are selective factor Xa inhibitors and were launched in Japan in April 2011 for venous thromboembolism (VTE). They were approved in the United States in January 2015 to reduce the risk of stroke and dangerous thrombosis (systemic embolism) in patients with atrial fibrillation caused by non-valvular heart disease. They entered China in December 2018 for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) with one or more risk factors (such as congestive heart failure, hypertension, age ≥75 years, diabetes, previous history of stroke or transient ischemic attack (TIA)). They are used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults, as well as to prevent recurrence of deep vein thrombosis and pulmonary embolism in adults. Its structure is as follows:
式(I)化合物叔丁基N-((1R,2S,5S)-2-(2-(5-氯吡啶-2-基)氨基)-2-氧乙酰基)氨基)-5-(二甲基氨基甲酰基)环己基)氨基甲酸酯是合成艾多沙班的一个重要中间产物:The compound of formula (I) tert-butyl N-((1R,2S,5S)-2-(2-(5-chloropyridin-2-yl)amino)-2-oxyacetyl)amino)-5-(dimethylcarbamoyl)cyclohexyl)carbamate is an important intermediate in the synthesis of edoxaban:
现有技术CN103214414A、CN102348688A、CN104761571A、CN107641131A、CN112940012A、CN104761571A、CN106459087A、CN104936961A、CN111763169A、US9809546B2等均采用将式(2)化合物与式(3)化合物在三乙胺的存在下反应:The prior art CN103214414A, CN102348688A, CN104761571A, CN107641131A, CN112940012A, CN104761571A, CN106459087A, CN104936961A, CN111763169A, US9809546B2, etc. all adopt the method of reacting the compound of formula (2) with the compound of formula (3) in the presence of triethylamine:
然而,上述现有技术公开的方法均存在难以搅拌均匀,反应均一性差,导致收率和纯度不高的问题,如CN103214414A公开的反应体系中存在大量的盐,导致反应凝固,搅拌困难,工业化放大生产反应均一性差,导致式(I)的产物产率较低,在工业水平上并不令人满意;CN111763169A公开的方法反应时间太长,50~60℃反应5~6h后,还需室温反应4-24h,反应时间长,反应条件不稳定,不利于工业化生产。However, the methods disclosed in the above-mentioned prior art all have the problem of difficulty in uniform stirring and poor reaction uniformity, resulting in low yield and purity. For example, the reaction system disclosed in CN103214414A contains a large amount of salt, which causes the reaction to solidify and makes stirring difficult. The reaction uniformity is poor in industrial scale-up production, resulting in a low yield of the product of formula (I), which is not satisfactory at the industrial level. The method disclosed in CN111763169A has a too long reaction time. After reacting at 50-60°C for 5-6h, it is necessary to react at room temperature for 4-24h. The reaction time is long and the reaction conditions are unstable, which is not conducive to industrial production.
现有技术CN105399667A公开了一种式(I)的制备方法,其通过式(4)化合物与式(5)化合物经缩合反应制得:Prior art CN105399667A discloses a preparation method of formula (I), which is prepared by condensing a compound of formula (4) with a compound of formula (5):
然而该反应需要先将式(4)化合物加入溶剂中调节pH,再与式(5)化合物进行缩合反应,缩合反应需要添加有机铋催化剂,催化剂的使用一方面增加了生产成本,另一方面还会造成金属铋残留,影响产品质量,不利于工业化生产。However, the reaction requires first adding the compound of formula (4) to a solvent to adjust the pH, and then conducting a condensation reaction with the compound of formula (5). The condensation reaction requires the addition of an organic bismuth catalyst. The use of the catalyst increases the production cost on the one hand, and also causes metal bismuth residue on the other hand, affecting the product quality and being unfavorable for industrial production.
现有技术CN113968813A、IN202041026059A公开了一种式(I)的制备方法,其通过式(6)化合物与式(7)化合物经缩合反应制得:Prior art CN113968813A and IN202041026059A disclose a preparation method of formula (I), which is prepared by condensing a compound of formula (6) with a compound of formula (7):
然而CN113968813A公开的反应采用N,N-二甲基甲酰胺作为反应溶剂,析出的产品纯度较差,需在85℃~95℃下反应6小时以上,并且需高温趁热抽滤,但即使这样纯度也未达到99%以上,且高温趁热甩滤工业化生产难以实现,存在极大的安全隐患;此外,N,N-二甲基甲酰胺长时间于高温碱性条件下,可能分解产生二甲胺杂质;IN202041026059A公开的工艺粗品收率不到80%,后处理增加了甲醇和水精制的工序,总收率不到75%。However, the reaction disclosed in CN113968813A uses N,N-dimethylformamide as the reaction solvent, and the purity of the precipitated product is poor. It needs to react at 85°C to 95°C for more than 6 hours and needs to be filtered while hot at high temperature. However, even so, the purity does not reach more than 99%, and high-temperature hot filtration is difficult to achieve industrial production, which poses a great safety hazard. In addition, N,N-dimethylformamide may decompose to produce dimethylamine impurities under high temperature alkaline conditions for a long time. The crude product yield of the process disclosed in IN202041026059A is less than 80%, and the post-treatment adds the process of methanol and water refining, and the total yield is less than 75%.
发明内容Summary of the invention
本发明的目的在于开发一种艾多沙班中间体的制备方法,使得所得产品收率高、杂质含量低,整个反应过程体系搅拌顺畅,不会出现固化及粘稠现象,未使用难处理或毒性试剂,环境友好,反应时间短,成本低,简化后处理工序,更适合产业化放大生产。The object of the present invention is to develop a method for preparing an edoxaban intermediate, so that the obtained product has a high yield and a low impurity content, the whole reaction process system is stirred smoothly, no solidification and viscosity phenomena occur, no difficult or toxic reagents are used, the method is environmentally friendly, the reaction time is short, the cost is low, the post-processing process is simplified, and the method is more suitable for industrialized scale-up production.
具体地,本发明提供一种式(I)化合物或其盐或水合物的制备方法,采用式(7)化合物与式(2)化合物在碱的作用下反应制得:Specifically, the present invention provides a method for preparing a compound of formula (I) or a salt or hydrate thereof, comprising reacting a compound of formula (7) with a compound of formula (2) under the action of a base to obtain:
在一个实施方式中,可先将式(7)化合物置于有机溶剂中,之后加入碱,升温搅拌,再加入式(2)化合物进行反应。In one embodiment, the compound of formula (7) can be placed in an organic solvent first, then a base is added, the temperature is raised and stirred, and then the compound of formula (2) is added to react.
进一步地,所述有机溶剂选自乙腈、N,N-二甲基甲酰胺或其混合,优选乙腈;所述碱选自三乙胺、N,N-二异丙基乙胺、吡啶或其混合,优选三乙胺。Furthermore, the organic solvent is selected from acetonitrile, N,N-dimethylformamide or a mixture thereof, preferably acetonitrile; the base is selected from triethylamine, N,N-diisopropylethylamine, pyridine or a mixture thereof, preferably triethylamine.
进一步地,所述式(2)化合物与所述碱的摩尔比为1:3.5~5.5,优选1:4.0-5.2。Furthermore, the molar ratio of the compound of formula (2) to the base is 1:3.5-5.5, preferably 1:4.0-5.2.
进一步地,所述式(2)化合物与所述式(7)化合物的摩尔比为1:1.1~1.5,优选1:1.1~1.2。Furthermore, the molar ratio of the compound of formula (2) to the compound of formula (7) is 1:1.1 to 1.5, preferably 1:1.1 to 1.2.
进一步地,所述升温为升温至45℃~55℃。Furthermore, the heating is to 45°C to 55°C.
在另一个实施方式中,将式(7)化合物置于有机溶剂中,之后加入与所述式(2)化合物的摩尔比为1.0~2.0:1的碱,升温搅拌,再加入与所述式(2)化合物的摩尔比为入2.0~4.0:1的碱及式(2)化合物进行反应;所述式(2)化合物与所述碱的总摩尔比为1:3.5~5.5,优选1:4.0-5.2。In another embodiment, the compound of formula (7) is placed in an organic solvent, and then a base is added in a molar ratio of 1.0 to 2.0:1 to the compound of formula (2), the temperature is raised and stirred, and then a base in a molar ratio of 2.0 to 4.0:1 to the compound of formula (2) and the compound of formula (2) are added to react; the total molar ratio of the compound of formula (2) to the base is 1:3.5 to 5.5, preferably 1:4.0-5.2.
在另一个实施方式中,将式(7)化合物置于有机溶剂中,之后加入与所述式(2)化合物的摩尔比为1.2~1.5:1的碱,升温搅拌,再加入与所述式(2)化合物的摩尔比为入3.0~4.0:1的碱及式(2)化合物进行反应;所述式(2)化合物与所述碱的总摩尔比为1:3.5~5.5,优选1:4.0-5.2。In another embodiment, the compound of formula (7) is placed in an organic solvent, and then a base is added in a molar ratio of 1.2 to 1.5:1 to the compound of formula (2), the temperature is raised and stirred, and then a base in a molar ratio of 3.0 to 4.0:1 to the compound of formula (2) and the compound of formula (2) are added to react; the total molar ratio of the compound of formula (2) to the base is 1:3.5 to 5.5, preferably 1:4.0-5.2.
在另一个实施方式中,将式(7)化合物置于有机溶剂中,之后加入与所述式(2)化合物的摩尔比为1.4:1的碱,升温搅拌,再加入与所述式(2)化合物的摩尔比为入3.8:1的碱及式(2)化合物进行反应;所述式(2)化合物与所述碱的总摩尔比为1:3.5~5.5,优选1:4.0-5.2。In another embodiment, the compound of formula (7) is placed in an organic solvent, and then a base is added in a molar ratio of 1.4:1 to the compound of formula (2), the temperature is raised and stirred, and then a base in a molar ratio of 3.8:1 to the compound of formula (2) and the compound of formula (2) are added to react; the total molar ratio of the compound of formula (2) to the base is 1:3.5-5.5, preferably 1:4.0-5.2.
进一步地,所述有机溶剂选自乙腈、N,N-二甲基甲酰胺或其混合,优选乙腈;所述碱选自三乙胺、N,N-二异丙基乙胺、吡啶或其混合,优选三乙胺。Furthermore, the organic solvent is selected from acetonitrile, N,N-dimethylformamide or a mixture thereof, preferably acetonitrile; the base is selected from triethylamine, N,N-diisopropylethylamine, pyridine or a mixture thereof, preferably triethylamine.
进一步地,所述式(2)化合物与所述式(7)化合物的摩尔比为1:1.1~1.5,优选1:1.1~1.2。Furthermore, the molar ratio of the compound of formula (2) to the compound of formula (7) is 1:1.1 to 1.5, preferably 1:1.1 to 1.2.
进一步地,所述升温为升温至45℃~55℃。Furthermore, the heating is to 45°C to 55°C.
在一个实施方式中,加入式(2)化合物后进行升温反应,反应毕降温,加水搅拌。In one embodiment, the compound of formula (2) is added and then the temperature is raised to react. After the reaction, the temperature is lowered and water is added and stirred.
进一步地,所述升温为升温至70℃~80℃;所述降温为降温至30℃~50℃。Furthermore, the heating is to 70°C to 80°C; and the cooling is to 30°C to 50°C.
进一步地,所述水用量与有机溶剂的用量质量比为1.0~1.5:1;优选地,所述水用量与乙腈的用量质量比为1.0~1.5:1。Furthermore, the mass ratio of the amount of water to the amount of the organic solvent is 1.0 to 1.5:1; preferably, the mass ratio of the amount of water to the amount of acetonitrile is 1.0 to 1.5:1.
为了避免先解离后反应生成较多盐,使得体系固化,从而影响搅拌以及反应均一性的问题,本发明先加入溶剂和式(7)化合物2-[(5-氯吡啶)氨基]-2-氧代乙酸乙酯,搅拌下分批次或一次性加入碱,升温搅拌后加入式(2)化合物(1S,2R,4S)-1-氨基-4-(二甲基氨基羰基)-环己基-2-氨基甲酸叔丁酯草酸盐进行反应,反应毕,待体系降温后,加入适量纯化水搅拌析晶,即得目标产物,收率可稳定在90%以上,产品总杂可控制在0.5%以下。In order to avoid the problem that dissociation first and then reaction generate more salts, so that the system solidifies, thereby affecting the stirring and reaction uniformity, the present invention first adds a solvent and a compound of formula (7) 2-[(5-chloropyridine)amino]-2-oxoethyl acetate, and adds a base in batches or all at once under stirring, and after heating and stirring, adds a compound of formula (2) (1S, 2R, 4S)-1-amino-4-(dimethylaminocarbonyl)-cyclohexyl-2-carbamic acid tert-butyl ester oxalate to react. After the reaction is completed, after the system is cooled, an appropriate amount of purified water is added and stirred for crystallization to obtain the target product. The yield can be stabilized at more than 90%, and the total impurities of the product can be controlled below 0.5%.
本发明所述的制备方法采用的溶剂可以与水互溶,整个反应过程体系搅拌顺畅,不会出现固化及粘稠现象,产品不易包裹溶剂,即使有少量溶剂残留,也可通过烘料过程去除;反应无需添加金属催化剂,更符合绿色化学的理念;直接采用游离碱2-[(5-氯吡啶)氨基]-2-氧代乙酸乙酯避免了先解离该物料会产生大量盐的问题,本发明的制备方法制备的产品收率高、杂质含量低,未使用难处理或毒性试剂,环境友好,反应过程无需长时间搅拌,反应时间短,成本低,简化后处理工序,更适合产业化放大生产。The solvent used in the preparation method of the present invention is miscible with water, the whole reaction process system is stirred smoothly, no solidification and viscosity phenomena occur, the product is not easy to wrap the solvent, even if a small amount of solvent remains, it can be removed by the drying process; the reaction does not need to add a metal catalyst, which is more in line with the concept of green chemistry; the free base 2-[(5-chloropyridine)amino]-2-oxoethyl acetate is directly used to avoid the problem of first dissociating the material to generate a large amount of salt; the product prepared by the preparation method of the present invention has high yield and low impurity content, does not use difficult-to-treat or toxic reagents, is environmentally friendly, does not need to stir for a long time in the reaction process, has a short reaction time, is low in cost, simplifies the post-processing process, and is more suitable for industrialized scale-up production.
具体实施方式DETAILED DESCRIPTION
下面代表性的实施例是为了更好地说明本发明,而非用于限制本发明的保护范围。以下实施例中使用的材料如无特殊说明均为商购获得。The following representative examples are intended to better illustrate the present invention, but are not intended to limit the scope of protection of the present invention. Unless otherwise specified, the materials used in the following examples were commercially available.
实施例1:式(I)化合物的制备Example 1: Preparation of the compound of formula (I)
反应瓶中加入170g乙腈,开启搅拌,加入20.1g(87.9mmol,1.1eq)2-[(5-氯吡啶)氨基]-2-氧代乙酸乙酯,加入11.3g(111.7mmol,1.4eq)三乙胺,加毕后,升温至50℃保温搅拌15min,再加入30.7g(303.4mmol,3.8eq)三乙胺和30g(79.9mmol,1.0eq)(1S,2R,4S)-1-氨基-4-(二甲基氨基羰基)-环己基-2-氨基甲酸叔丁酯草酸盐,升至80℃保温搅拌4h,将体系温度降至50℃以下,向上述反应液中加入250g纯化水,冷却至10℃保温搅拌2h。过滤,滤饼用30g纯化水淋洗,烘干后得到白色固体34.9g,收率93.4%,纯度99.5%。170 g of acetonitrile was added to the reaction flask, stirring was started, 20.1 g (87.9 mmol, 1.1 eq) of ethyl 2-[(5-chloropyridine)amino]-2-oxoacetate was added, and 11.3 g (111.7 mmol, 1.4 eq) of triethylamine was added. After the addition was completed, the temperature was raised to 50°C and stirred for 15 min. Then 30.7 g (303.4 mmol, 3.8 eq) of triethylamine and 30 g (79.9 mmol, 1.0 eq) (1S, 2R, 4S)-1-amino-4-(dimethylaminocarbonyl)-cyclohexyl-2-carbamic acid tert-butyl ester oxalate were added, the temperature was raised to 80°C and stirred for 4 h. The system temperature was lowered to below 50°C. 250 g of purified water was added to the above reaction solution, and the solution was cooled to 10°C and stirred for 2 h. The filter cake was filtered and rinsed with 30 g of purified water. After drying, 34.9 g of white solid was obtained with a yield of 93.4% and a purity of 99.5%.
实施例2:式(I)化合物的制备Example 2: Preparation of the compound of formula (I)
反应釜中加入170kg乙腈,开启搅拌,加入21.9kg(95.8mol,1.2eq)2-[(5-氯吡啶)氨基]-2-氧代乙酸乙酯,加入11.3kg(111.7mol,1.4eq)三乙胺,加毕后,升温至50℃保温搅拌15min,再加入30.7kg(303.4mol,3.8eq)三乙胺和30kg(79.9mol,1.0eq)(1S,2R,4S)-1-氨基-4-(二甲基氨基羰基)-环己基-2-氨基甲酸叔丁酯草酸盐,升至70℃保温搅拌4h,将体系温度降至50℃以下,向上述反应液中加入250kg纯化水,冷却至10℃保温搅拌2h。甩滤,滤饼用30kg纯化水淋洗,烘干后得到白色固体34.8kg,收率93.1%,纯度99.9%。170 kg of acetonitrile was added to the reaction kettle, stirring was started, 21.9 kg (95.8 mol, 1.2 eq) of ethyl 2-[(5-chloropyridine)amino]-2-oxoacetate was added, and 11.3 kg (111.7 mol, 1.4 eq) of triethylamine was added. After the addition was completed, the temperature was raised to 50°C and stirred for 15 min. Then 30.7 kg (303.4 mol, 3.8 eq) of triethylamine and 30 kg (79.9 mol, 1.0 eq) (1S, 2R, 4S)-1-amino-4-(dimethylaminocarbonyl)-cyclohexyl-2-carbamic acid tert-butyl ester oxalate were added, the temperature was raised to 70°C and stirred for 4 h. The system temperature was lowered to below 50°C. 250 kg of purified water was added to the above reaction solution, and the reaction solution was cooled to 10°C and stirred for 2 h. The filter cake was filtered and rinsed with 30 kg of purified water. After drying, 34.8 kg of white solid was obtained with a yield of 93.1% and a purity of 99.9%.
实施例3:式(I)化合物的制备Example 3: Preparation of the compound of formula (I)
反应瓶中加入170g乙腈,开启搅拌,加入21.9g(95.8mmol,1.2eq)2-[(5-氯吡啶)氨基]-2-氧代乙酸乙酯,加入32g(316.2mmol,4.0eq)三乙胺,升温至50℃保温搅拌15min,搅拌下加入30g(79.9mmol,1.0eq)(1S,2R,4S)-1-氨基-4-(二甲基氨基羰基)-环己基-2-氨基甲酸叔丁酯草酸盐,升至75℃保温搅拌4h,将体系温度降至50℃以下,向上述反应液中加入250g纯化水,冷却至10℃保温搅拌2h。过滤,滤饼用30g纯化水淋洗,烘干后得到白色固体34.2g,收率91.5%,纯度99.6%。170g acetonitrile was added to the reaction bottle, stirring was started, 21.9g (95.8mmol, 1.2eq) ethyl 2-[(5-chloropyridine)amino]-2-oxoacetate was added, 32g (316.2mmol, 4.0eq) triethylamine was added, the temperature was raised to 50°C and stirred for 15min, 30g (79.9mmol, 1.0eq) (1S, 2R, 4S)-1-amino-4-(dimethylaminocarbonyl)-cyclohexyl-2-carbamic acid tert-butyl ester oxalate was added under stirring, the temperature was raised to 75°C and stirred for 4h, the system temperature was lowered to below 50°C, 250g purified water was added to the above reaction solution, the mixture was cooled to 10°C and stirred for 2h. Filter, rinse the filter cake with 30g purified water, and dry to obtain 34.2g white solid with a yield of 91.5% and a purity of 99.6%.
实验例4:式(I)化合物的制备Experimental Example 4: Preparation of the compound of formula (I)
反应瓶中加入170g乙腈,开启搅拌,加入21.9g(95.8mmol,1.2eq)2-[(5-氯吡啶)氨基]-2-氧代乙酸乙酯,加入42g(415.1mmol,5.2eq)三乙胺,升温至50℃保温搅拌15min,搅拌下加入30g(79.9mmol,1.0eq)(1S,2R,4S)-1-氨基-4-(二甲基氨基羰基)-环己基-2-氨基甲酸叔丁酯草酸盐,升至75℃保温搅拌4h,将体系温度降至50℃以下,向上述反应液中加入250g纯化水,冷却至10℃保温搅拌2h。过滤,滤饼用30g纯化水淋洗,烘干后得到白色固体34.7g,收率92.7%,纯度99.7%。170g acetonitrile was added to the reaction bottle, stirring was started, 21.9g (95.8mmol, 1.2eq) ethyl 2-[(5-chloropyridine)amino]-2-oxoacetate was added, 42g (415.1mmol, 5.2eq) triethylamine was added, the temperature was raised to 50°C and stirred for 15min, 30g (79.9mmol, 1.0eq) (1S, 2R, 4S)-1-amino-4-(dimethylaminocarbonyl)-cyclohexyl-2-carbamic acid tert-butyl ester oxalate was added under stirring, the temperature was raised to 75°C and stirred for 4h, the system temperature was lowered to below 50°C, 250g purified water was added to the above reaction solution, the mixture was cooled to 10°C and stirred for 2h. Filter, rinse the filter cake with 30g purified water, and dry to obtain 34.7g white solid with a yield of 92.7% and a purity of 99.7%.
对比实施例1:式(I)化合物的制备Comparative Example 1: Preparation of the compound of formula (I)
反应瓶中加入170g乙腈,开启搅拌,加入25.4g(95.8mmol,1.2eq)2-[(5-氯吡啶)氨基]-2-氧代乙酸乙酯盐酸盐,再加入42g(415.1mmol,5.2eq)三乙胺和30g(79.9mmol,1.0eq)(1S,2R,4S)-1-氨基-4-(二甲基氨基羰基)-环己基-2-氨基甲酸叔丁酯草酸盐,体系固化导致搅拌困难,升至75℃(升温后体系仍很粘稠,并含有较多块状固体),保温搅拌4h,将体系温度降至50℃以下,向上述反应液中加入250g纯化水,冷却至10℃保温搅拌2h。过滤,滤饼用30g纯化水淋洗,烘干后得到白色固体31.0g,收率82.9%,纯度97.8%。对比实施例2:式(I)化合物的制备170g acetonitrile was added to the reaction bottle, stirring was started, 25.4g (95.8mmol, 1.2eq) ethyl 2-[(5-chloropyridine)amino]-2-oxoacetate hydrochloride was added, and then 42g (415.1mmol, 5.2eq) triethylamine and 30g (79.9mmol, 1.0eq) (1S, 2R, 4S)-1-amino-4-(dimethylaminocarbonyl)-cyclohexyl-2-carbamic acid tert-butyl ester oxalate were added. The system solidified and stirring was difficult. The temperature was raised to 75°C (the system was still very viscous after heating and contained a lot of blocky solids), and the temperature was kept and stirred for 4h. The system temperature was lowered to below 50°C, 250g purified water was added to the above reaction solution, and the mixture was cooled to 10°C and stirred for 2h. Filter, rinse the filter cake with 30g purified water, and dry to obtain 31.0g white solid, with a yield of 82.9% and a purity of 97.8%. Comparative Example 2: Preparation of the compound of formula (I)
反应瓶中加入170g乙腈,开启搅拌,加入18.3g(79.9mmol,1.0eq)2-[(5-氯吡啶)氨基]-2-氧代乙酸乙酯,加入42g(415.1mmol,5.2eq)三乙胺,搅拌下加入30g(79.9mmol,1.0eq)(1S,2R,4S)-1-氨基-4-(二甲基氨基羰基)-环己基-2-氨基甲酸叔丁酯草酸盐,升至65℃保温搅拌4h,将体系温度降至50℃以下,向上述反应液中加入250g纯化水,冷却至10℃保温搅拌2h。过滤,滤饼用30g纯化水淋洗,烘干后得到白色固体29.5g,收率78.9%,纯度98.3%。170g acetonitrile was added to the reaction bottle, stirring was started, 18.3g (79.9mmol, 1.0eq) ethyl 2-[(5-chloropyridine)amino]-2-oxoacetate was added, 42g (415.1mmol, 5.2eq) triethylamine was added, 30g (79.9mmol, 1.0eq) (1S, 2R, 4S)-1-amino-4-(dimethylaminocarbonyl)-cyclohexyl-2-carbamic acid tert-butyl ester oxalate was added under stirring, the temperature was raised to 65°C and stirred for 4h, the system temperature was lowered to below 50°C, 250g purified water was added to the above reaction solution, and the mixture was cooled to 10°C and stirred for 2h. Filter, rinse the filter cake with 30g purified water, and dry to obtain 29.5g white solid, with a yield of 78.9% and a purity of 98.3%.
对比实施例3:式(I)化合物的制备Comparative Example 3: Preparation of the compound of formula (I)
反应瓶中加入170g乙腈,开启搅拌,加入30g(79.9mmol,1.0eq)(1S,2R,4S)-1-氨基-4-(二甲基氨基羰基)-环己基-2-氨基甲酸叔丁酯草酸盐和42g(415.1mmol,5.2eq)三乙胺,加毕后,升温至50℃保温搅拌15min,再加入21.9(95.8mmol,1.2eq)2-[(5-氯吡啶)氨基]-2-氧代乙酸乙酯,体系固化,升至75℃保温搅拌4h,将体系温度降至50℃以下,向上述反应液中加入250g纯化水,冷却至10℃保温搅拌2h。过滤,滤饼用30g纯化水淋洗,烘干后得到白色固体26.6g,收率71.1%,纯度99.2%。170g acetonitrile was added to the reaction bottle, stirring was started, 30g (79.9mmol, 1.0eq) (1S, 2R, 4S)-1-amino-4-(dimethylaminocarbonyl)-cyclohexyl-2-carbamic acid tert-butyl ester oxalate and 42g (415.1mmol, 5.2eq) triethylamine were added, and the temperature was raised to 50°C and stirred for 15min, and then 21.9 (95.8mmol, 1.2eq) ethyl 2-[(5-chloropyridine)amino]-2-oxoacetate was added, the system solidified, the temperature was raised to 75°C and stirred for 4h, the system temperature was lowered to below 50°C, 250g purified water was added to the above reaction solution, and the mixture was cooled to 10°C and stirred for 2h. Filter, rinse the filter cake with 30g purified water, and dry to obtain 26.6g white solid, with a yield of 71.1% and a purity of 99.2%.
对比实施例4:式(I)化合物的制备Comparative Example 4: Preparation of the compound of formula (I)
反应瓶中加入170g乙腈,开启搅拌,加入21.9g(95.8mmol,1.2eq)2-[(5-氯吡啶)氨基]-2-氧代乙酸乙酯,加入11.3g(111.7mmol,1.4eq)三乙胺,加毕后,升温至50℃保温搅拌15min,再加入14.5g(143.3mmol,1.8eq)三乙胺和30g(79.9mmol,1.0eq)(1S,2R,4S)-1-氨基-4-(二甲基氨基羰基)-环己基-2-氨基甲酸叔丁酯草酸盐,升至70℃保温搅拌4h,将体系温度降至50℃以下,向上述反应液中加入250g纯化水,冷却至10℃保温搅拌2h。过滤,滤饼用30g纯化水淋洗,烘干后得到白色固体30.9g,收率82.6%,纯度98.9%。对比实施例5:式(I)化合物的制备170 g of acetonitrile was added to the reaction flask, stirring was started, 21.9 g (95.8 mmol, 1.2 eq) of ethyl 2-[(5-chloropyridine)amino]-2-oxoacetate was added, and 11.3 g (111.7 mmol, 1.4 eq) of triethylamine was added. After the addition was completed, the temperature was raised to 50°C and stirred for 15 min. Then 14.5 g (143.3 mmol, 1.8 eq) of triethylamine and 30 g (79.9 mmol, 1.0 eq) of (1S, 2R, 4S)-1-amino-4-(dimethylaminocarbonyl)-cyclohexyl-2-carbamic acid tert-butyl ester oxalate were added, the temperature was raised to 70°C and stirred for 4 h. The system temperature was lowered to below 50°C. 250 g of purified water was added to the above reaction solution, and the solution was cooled to 10°C and stirred for 2 h. The filter cake was filtered and rinsed with 30 g of purified water, and dried to obtain 30.9 g of a white solid with a yield of 82.6% and a purity of 98.9%. Comparative Example 5: Preparation of the compound of formula (I)
反应瓶中加入170g乙腈,开启搅拌,加入18.3g(79.9mmol,1.0eq)2-[(5-氯吡啶)氨基]-2-氧代乙酸乙酯,加入11.3g(111.7mmol,1.4eq)三乙胺,加毕后,升温至50℃保温搅拌15min,再加入30.7g(303.4mmol,3.8eq)三乙胺和30g(79.9mmol,1.0eq)(1S,2R,4S)-1-氨基-4-(二甲基氨基羰基)-环己基-2-氨基甲酸叔丁酯草酸盐,升至70℃保温搅拌4h,将体系温度降至50℃以下,向上述反应液中加入250g纯化水,冷却至10℃保温搅拌2h。过滤,滤饼用30g纯化水淋洗,烘干后得到白色固体31.4g,收率84.0%,纯度99.2%。170 g of acetonitrile was added to the reaction flask, stirring was started, 18.3 g (79.9 mmol, 1.0 eq) of ethyl 2-[(5-chloropyridine)amino]-2-oxoacetate was added, and 11.3 g (111.7 mmol, 1.4 eq) of triethylamine was added. After the addition was completed, the temperature was raised to 50°C and stirred for 15 min. Then 30.7 g (303.4 mmol, 3.8 eq) of triethylamine and 30 g (79.9 mmol, 1.0 eq) of (1S, 2R, 4S)-1-amino-4-(dimethylaminocarbonyl)-cyclohexyl-2-carbamic acid tert-butyl ester oxalate were added, the temperature was raised to 70°C and stirred for 4 h. The system temperature was lowered to below 50°C. 250 g of purified water was added to the above reaction solution, and the solution was cooled to 10°C and stirred for 2 h. The filter cake was filtered and rinsed with 30 g of purified water. After drying, 31.4 g of white solid was obtained with a yield of 84.0% and a purity of 99.2%.
尽管以上已经对本发明作了详细描述,但是本领域技术人员理解,在不偏离本发明的精神和范围的前提下可以对本发明进行各种改变、替换和变更。本发明的权利范围并不限于上文所作的详细描述,而应归属于权利要求书。Although the present invention has been described in detail above, it is understood by those skilled in the art that various changes, substitutions and modifications may be made to the present invention without departing from the spirit and scope of the present invention. The scope of the present invention is not limited to the detailed description above, but should be attributed to the claims.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310192696.1A CN118580183A (en) | 2023-03-02 | 2023-03-02 | A method for preparing an edoxaban intermediate |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310192696.1A CN118580183A (en) | 2023-03-02 | 2023-03-02 | A method for preparing an edoxaban intermediate |
Publications (1)
Publication Number | Publication Date |
---|---|
CN118580183A true CN118580183A (en) | 2024-09-03 |
Family
ID=92536066
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310192696.1A Pending CN118580183A (en) | 2023-03-02 | 2023-03-02 | A method for preparing an edoxaban intermediate |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN118580183A (en) |
-
2023
- 2023-03-02 CN CN202310192696.1A patent/CN118580183A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2023174449A1 (en) | Method for preparing n-(3-chloro-4-(2-pyridylmethoxy)phenyl)-2-cyanoacetamide | |
US10538507B2 (en) | Preparation process for high-purity dabigatran etexilate | |
CN110452222B (en) | Preparation method of vonoprazan fumarate | |
CN104591959B (en) | A kind of preparation method of stilbene compound | |
CN118580183A (en) | A method for preparing an edoxaban intermediate | |
CN109320441B (en) | Method for efficiently preparing alkynylamide compound | |
CN106831536B (en) | Preparation method of gliclazide synthesis process | |
WO2024113743A1 (en) | Method for preparing hexachlorocyclotriphosphazene | |
CN115557882A (en) | Preparation method of (R) -1-Boc-3-aminopiperidine | |
CN114560862A (en) | Synthesis method of pyrrolo [1,2-A ] quinoxaline-4 (5H) -ketone and derivative thereof | |
CN111057007B (en) | A functionalized ionic liquid based on a dual-core structure, its preparation method, and its use method for degrading lignocellulose | |
CN116621781A (en) | A kind of preparation method of 2-(3-nitrophenyl)-4,5-dihydro-1H-imidazoline | |
CN109810052B (en) | Simple and convenient preparation method of high-selectivity apatinib | |
CN110698381A (en) | Method for synthesizing N- (benzyloxycarbonyl) succinimide by one-pot two-phase method | |
CN116178251A (en) | Preparation method of edoxaban intermediate | |
CN112851577A (en) | Preparation method of regorafenib | |
WO2024120275A1 (en) | Preparation method for edoxaban and intermediate thereof | |
CN113354623B (en) | Preparation method of ilaprazole key intermediate 5- (1H-pyrrole-1-yl) -2-mercaptobenzimidazole | |
CN118724801B (en) | Preparation method of intermediate of toluene sulfonic acid Ai Duosha class | |
CN104163778A (en) | Method for preparing p-amino-benzamidine hydrochloride | |
CN110396059A (en) | A kind of synthetic method of 5- cyanoindole | |
CN104628770B (en) | Preparation method of risedronate sodium | |
JP2527599B2 (en) | Method for producing amidoalkanesulfonic acid | |
RU2741389C1 (en) | Method for preparing intermediate compound for synthesis of medicinal agent | |
WO2016034150A1 (en) | Method for preparing bosutinib and crystal thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |